Is a Pre-Operative Brain Natriuretic Peptide or N-Terminal Pro–B-Type Natriuretic Peptide Measurement an Independent Predictor of Adverse Cardiovascular Outcomes Within 30 Days of Noncardiac Surgery? A Systematic Review and Meta-Analysis of Observational Studies by Karthikeyan, Ganesan et al.
C
*
I
Journal of the American College of Cardiology Vol. 54, No. 17, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PBiomarkers and Cardiac Surgery
CMEIs a Pre-Operative Brain Natriuretic Peptide
or N-Terminal Pro–B-Type Natriuretic Peptide
Measurement an Independent Predictor of
Adverse Cardiovascular Outcomes Within
30 Days of Noncardiac Surgery?
A Systematic Review and Meta-Analysis of Observational Studies
Ganesan Karthikeyan, MD, DM,*†‡ Ross A. Moncur, BSC,¶ Oren Levine, BSC,#
Diane Heels-Ansdell, MSC,‡ Matthew T. V. Chan, MD, MSC,** Pablo Alonso-Coello, MD, MSC,††‡‡
Salim Yusuf, MBBS, DPHIL,*†‡ Daniel Sessler, MD,§§ Juan Carlos Villar, MD, PHD,
Otavio Berwanger, MD, PHD,¶¶ Matthew McQueen, MB, CHB, PHD,†§ Anna Mathew, MD,##
Stephen Hill, PHD,§ Simon Gibson, MD,*** Colin Berry, MD,††† Huei-Ming Yeh, MD,‡‡‡
P. J. Devereaux, MD, PHD†‡
New Delhi, India; Hamilton, Kingston, and London, Ontario, Canada; Hong Kong, China; Barcelona, Spain;
Cleveland, Ohio; Bogotá, Colombia; Sao Paulo, Brazil; Glasgow, United Kingdom; and Taipei, Taiwan
Objectives We conducted a systematic review and meta-analysis to determine if pre-operative brain natriuretic peptide
(BNP) (i.e., BNP or N-terminal pro–B-type natriuretic peptide [NT-proBNP]) is an independent predictor of 30-day
adverse cardiovascular outcomes after noncardiac surgery.
Background Pre-operative clinical cardiac risk indices have only modest predictive power. BNP predicts adverse cardiovascular
outcomes in a variety of nonsurgical settings and may similarly predict these outcomes in the perioperative setting.
Methods We employed 5 search strategies (e.g., searching bibliographic databases), and we included all studies that as-
sessed the independent prognostic value of pre-operative BNP measurement as a predictor of cardiovascular
complications after noncardiac surgery. We determined study eligibility and conducted data abstraction indepen-
dently and in duplicate. We calculated a pooled odds ratio using a random effects model.
Results Nine studies met eligibility criteria, and included a total of 3,281 patients, among whom 314 experienced 1 or
more perioperative cardiovascular complications. The average proportion of patients with elevated BNP was
24.8% (95% confidence interval [CI]: 20.1 to 30.4%; I2  89%). All studies showed a statistically significant as-
sociation between an elevated pre-operative BNP level and various cardiovascular outcomes (e.g., a composite
of cardiac death and nonfatal myocardial infarction; atrial fibrillation). Data pooled from 7 studies demonstrated
an odds ratio (OR) of 19.3 (95% CI: 8.5 to 43.7; I2  58%). The pre-operative BNP measurement was an inde-
pendent predictor of perioperative cardiovascular events among studies that only considered the outcomes of
death, cardiovascular death, or myocardial infarction (OR: 44.2, 95% CI: 7.6 to 257.0, I2  51.6%), and those
that included other outcomes (OR: 14.7, 95% CI: 5.7 to 38.2, I2  62.2%); the p value for interaction was 0.28.
Conclusions These results suggest that an elevated pre-operative BNP or NT-proBNP measurement is a powerful, indepen-
dent predictor of cardiovascular events in the first 30 days after noncardiac surgery. (J Am Coll Cardiol 2009;
54:1599–606) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.028§Pathology and Molecular Medicine, Population Health Research Institute, Ham-ontinuing Medical Education (CME) is available for this article. From the
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Pre-Operative BNP and Perioperative Risk October 20, 2009:1599–606A recent study used surgical data
from 56 countries to estimate that
230 million major surgical pro-
cedures are undertaken annually
worldwide (1). Given that cardiac
and pediatric surgery account only
for a minority of major surgical
cases, at least 200 million adults
annually undergo major noncar-
diac surgery. Several million of
these patients suffer a major car-
diovascular complication within 30
days of their surgery (2).
Establishing a method to facilitate accurate pre-operative
ssessment of major perioperative cardiovascular risk serves
number of important purposes. Accurate risk estimates
rovide guidance to physicians for perioperative manage-
ent, including the choice of anesthetic techniques and the
ocation and intensity of post-operative care. Accurate
See page 1607
re-operative risk assessment also allows patients and phy-
icians to make informed decisions about the appropriate-
ess of surgery. For example, some patients may find their
isk of a major perioperative cardiac complication unaccept-
ble and may choose to forgo or defer surgery (e.g., to
xperience an important life event).
Many surgical patients have limited activity levels because
f their underlying disease states (e.g., arthritis, peripheral
ascular disease, cancer). These patients may have underly-
ng cardiac disease but are not sufficiently active to exhibit
ymptoms. Consequently, clinical cardiovascular risk indices
ave only modest predictive power in patients undergoing
ajor noncardiac surgery (2,3). To enhance risk prediction,
esearchers have assessed the added value of noninvasive
ardiac testing (e.g., dobutamine echocardiography, dipy-
idamole stress perfusion imaging) before noncardiac sur-
ery (4,5). Although data are limited, these tests appear to
rovide additional predictive value beyond clinical variables,
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alud Pública (CIBERESP), Barcelona, Spain; §§Department of Outcomes Re-
earch, The Cleveland Clinic, Cleveland, Ohio;  Facultad de Medicina, Universidad
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Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
OR  odds ratioS
Manuscript received January 22, 2009; revised manuscript received May 11, 2009,
ccepted June 1, 2009.ut are costly and time consuming (4,5). Therefore, there
emains a need for a fast, simple, and cost-effective method
o enhance pre-operative cardiovascular risk assessment.
Ventricular cardiomyocytes secrete brain natriuretic pep-
ide (BNP), a prohormone, and its inactive cleavage product
-terminal fragment (N-terminal-pro–B-type natriuretic
eptide [NT-proBNP]) into the blood in response to atrial
r ventricular wall stretch (6), or myocardial ischemia (7).
hroughout the rest of the paper, we will use the term BNP
o represent either BNP or NT-proBNP unless otherwise
tated.
Plasma BNP is a powerful predictor of death and major
dverse cardiovascular events in patients with stable coro-
ary artery disease (8), acute coronary syndromes (9), and
ongestive heart failure (10). A few recent studies have
uggested that pre-operative elevation of BNP predicts
ajor perioperative cardiovascular complications in patients
ndergoing noncardiac surgery. An accurate understanding
f this potential association requires a comprehensive, sys-
ematic, and unbiased assessment of the literature. We
herefore undertook a systematic review and meta-analysis
o address the following question: in patients undergoing
oncardiac surgery, is pre-operative BNP blood concentra-
ion an independent predictor of adverse cardiovascular
utcomes within 30 days of surgery?
ethods
tudy eligibility. We included studies of noncardiac sur-
ery patients who had a BNP measurement before surgery,
nd the authors reported the independent association be-
ween a pre-operative BNP measurement and a periopera-
ive cardiovascular event up to 30 days after surgery. A priori
e defined a perioperative cardiovascular event as 1 or more
f the following events: death, cardiac death, cardiovascular
eath, myocardial infarction (MI), acute coronary syn-
rome, unstable angina, coronary artery revascularization,
ardiac arrest, cardiac arrhythmia resulting in hemodynamic
ompromise or requiring an intervention, congestive heart
ailure, or rehospitalization due to a cardiac cause.
Studies were excluded if they involved patients under 18
ears of age. If studies did not restrict outcomes to the first
0 days after surgery, did not report the independent
ssociation of an elevated BNP level with cardiovascular
vents, or did not report BNP results based on a threshold
alue (i.e., they only reported results for BNP as a contin-
ous variable), we attempted to contact the authors to
btain these missing data. If we were unable to obtain these
ata, the study was excluded.
earch strategy. We undertook 5 strategies to identify
otentially eligible studies. Our search included the follow-
ng: 5 electronic bibliographic databases; hand searching
bstracts of the annual meetings of the American College of
ardiology, American Heart Association, and European
ociety of Cardiology between 1997 and 2007; reference
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October 20, 2009:1599–606 Pre-Operative BNP and Perioperative Riskists of the retrieved articles, review articles, and practice
uidelines; our own files; and contact with experts.
Using all the studies of which we were initially aware, we
dentified medical subject heading terms and key words for
he search. In each database, we undertook an iterative
rocess to refine the search strategy through testing of
everal search terms and incorporation of new search terms
s new relevant citations were identified. We searched the
vid version of MEDLINE (Ovid MEDLINE in-process
nd other nonindexed citations and Ovid MEDLINE,
950 to third week of April, 2008), EMBASE (1980 to
008, week 15), the Cochrane Central Register of Con-
rolled Trials (first quarter 2008), the Cochrane Database of
ystematic Reviews (first quarter 2008), and the ACP
ournal Club (1991 to March/April 2008). No language
estrictions were applied. All searches were performed using
he OvidSP search engine (Ovid Technologies, Inc., New
ork, New York). The search strategy is detailed in the
nline Appendix.
ligibility assessment. Teams of 2 persons independently
creened the title and abstract of each citation identified in
ur search. They selected any citation that they suspected
ad any possibility of fulfilling our eligibility criteria to
ndergo full review. If either of the 2 reviewers of a citation
dentified a citation as potentially relevant, we obtained the
ull-text article for full review.
Teams of 2 persons independently determined the eligi-
ility of all studies identified to undergo full text evaluation
n our screening process. Disagreements were resolved by a
onsensus process of having the 2 reviewers discuss their
ationale regarding the study’s eligibility, and when this did
ot resolve differences, a third person made a final decision
n the study’s eligibility.
ata abstraction and validity assessment. We abstracted
he following descriptive data from all eligible studies: study
esign, study period, sample size, patient population, type of
urgery, number of participants, length of follow-up, out-
ome, marker evaluated (i.e., BNP or NT-proBNP), assay
anufacturer, BNP threshold, timing of BNP measure-
ent, and the proportion of patients with an elevated BNP
easurement. We evaluated the following validity criteria:
linding of data collectors and outcome adjudicators to
NP values, consistency of outcome assessment (whether
he outcome assessment was the same for all study partici-
ants), and variables adjusted for in the analyses.
Two persons independently abstracted data from all
tudies that fulfilled our eligibility criteria, and we resolved
isagreements using the same consensus process discussed
bove. We contacted the authors of all eligible studies to
btain missing data or confirm the accuracy of the ab-
tracted data.
Statistical analyses. Interobserver agreement of study
ligibility and the validity criteria between reviewers was
ssessed using a weighted kappa (determined by the PC-
gree Program, McMaster University, Hamilton, Ontario,
anada). eThree of the studies that we included in our meta-analysis
id not report the odds ratio we required. The authors of 1
tudy (Gibson et al. [11]) provided their raw data, and we
ere thus able to perform a logistic regression analysis,
djusting for sex, ischemic heart disease, heart failure,
erebrovascular disease, renal impairment, type of surgery,
nd the prescription of beta-blockers and statins. These
ere the variables they had used in their reported analysis
ased upon a continuous BNP value. The study by Mahla
t al. (12) focused on post-operative BNP, but they had also
ollected a pre-operative BNP sample. Dr. Mahla per-
ormed a multivariable logistic regression using pre-
perative BNP instead of post-operative BNP and provided
s with the results. In the paper by Yeh et al. (13), only the
value for the pre-operative BNP measurement was re-
orted from their multivariable analysis but not the odds
atio. The authors were contacted, and they provided us
ith the odds ratio (13).
To determine the proportion of patients with an elevated
NP value across studies, we used the inverse-variance
ethod to pool the results across studies. The outcomes
aried among the studies, and were mostly composite
utcomes. One person (P.J.D.), blinded to the study and
tudy results, assessed the prognostic similarity of the each
tudy’s outcome and decided whether it was reasonable to
nclude the study results in a pooled analysis. For the studies
elected, we pooled the adjusted odds ratios using the
erSimonian and Laird random effects model (14). We
alculated the I2 statistic to assess heterogeneity between
tudies. An I2 value 25% was considered to represent
ignificant heterogeneity (15). Our a priori hypotheses to
xplain significant heterogeneity in the direction and mag-
itude of effect were: 1) BNP type (BNP vs. NT-proBNP);
) type of surgery (major vascular, intra-abdominal, or
ntrathoracic vs. other); 3) blinding of data collectors (yes vs.
o); 4) blinding of outcome adjudicators (yes vs. no); and
) number of known predictors (i.e., diabetes mellitus, renal
ailure, coronary artery disease, congestive heart failure,
troke/transient ischemic attack, or high-risk surgery [intra-
bdominal, intrathoracic, or vascular surgery]) adjusted for
n analysis (2 or fewer vs. other).
We also performed sensitivity analyses to determine if the
redictive power of BNP varied between studies that evaluated
he outcomes of death, cardiovascular death, or MI, compared
o studies that evaluated outcomes that only, or also, evaluated
ther less prognostically important events as part of their
utcome. All p values were 2-sided and a value 0.05 was
onsidered statistically significant. Analyses were performed
sing S-PLUS version 8.0 (TIBCO, Seattle, Washington).
esults
ur initial search yielded 564 references. We eliminated
29 citations after preliminary screening. The full texts of
he remaining 35 articles were scrutinized to determine
ligibility. Nine studies fulfilled our eligibility criteria and are
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Pre-Operative BNP and Perioperative Risk October 20, 2009:1599–606ncluded in this systematic review (Fig. 1) (11–13,16–21).
wenty-six studies were excluded during the full text
eview; reasons for exclusions are reported in Figure 1.
Data from a preliminary study of a small number of
atients (22) was also reported in a subsequent larger study
y the same group of investigators (11). Only the latter
tudy was included in our analysis. There were 4 studies
rom 1 group of investigators reporting data from the same
enters and across overlapping periods, and what appeared
o be overlapping patient populations (16,23–25). We
ncluded the largest of these reports, which fulfilled our
ligibility criteria (16). Interobserver agreement for the
ecisions around study eligibility was good (weighted kappa
Figure 1 Flow Chart Showing Selection of Studies
*Independent association of pre-operative brain natriuretic peptide (BNP) levels
not reported with outcomes of interest, n  14; data overlapped with other
reports, n  4; 30-day outcomes not available, n  3; patients did not
undergo a surgical procedure, n  1; patients underwent cardiopulmonary
bypass as part of surgery, n  1; no pre-operative BNP value available, n  1;
BNP analyzed as a continuous variable, n  1; case report, n  1.
haracteristics of Included StudiesTable 1 Characteristics of Included Studies
Author, Year (Ref. #) Study Period*
Patient
Population
Dernellis and Panaretou, 2006 (20) Not reported Elective
Cuthbertson et al., 2007 (18) Sept 2004 to Dec 2005 Elective
Cuthbertson et al, 2007 (19) Jan 2006 to June 2006 Emergent
Yun et al., 2008 (21) Jan 2006 to Dec 2006 Elective
Mahla et al., 2007 (12) Oct 2002 to June 2003 Elective
Yeh et al., 2005 (13) Nov 2002 to Aug 2003 Elective
Gibson et al., 2007 (11) April 2004 to Oct 2005 Elective
Feringa et al., 2006 (16) Oct 2003 to Dec 2004 Elective
Cardinale et al., 2007 (17) Oct 2004 to Dec 2005 ElectiveStudy period is the time across which included patients underwent surgery. †Median. ‡As per separate.64). We were able to contact an author for 7 of the 9
tudies that fulfilled our eligibility criteria to confirm ab-
tracted or obtain missing data. We sent the 2 remaining
uthors information on the data we abstracted from their
tudies and asked them to contact us if we had misunder-
tood any of their data.
haracteristics of included studies. All studies were pro-
pective cohort studies. Table 1 presents the details of the
ncluded studies. The average age of the patients enrolled in
hese studies ranged between 57 and 74 years. Eight of the
ligible studies included elective surgery patients, and the
inth study included emergent surgery patients (19). Pa-
ients underwent a wide range of different surgical proce-
ures across the included studies. Two studies included only
atients who underwent vascular surgery (12,16), and vas-
ular surgery constituted a major proportion of the surgeries
n 3 other studies (11,13,18).
re-operative BNP/NT pro-BNP measurement. The
iming of pre-operative BNP measurement ranged from 21
ays before surgery to immediately before the procedure.
ive of the 9 studies used the NT-proBNP assay from
oche Diagnostics (Hoffmann-La Roche Ltd., Basel, Swit-
erland). The decision threshold used in the studies varied
idely between 40 and 189 pg/ml for BNP and between
01 and 533 pg/ml for NT-proBNP (Table 2). The pooled
nalysis demonstrated that the proportion of patients with
n elevated BNP value across studies was 24.8% (95%
onfidence interval [CI]: 20.1 to 30.4%; I2  89%).
ethodologic quality of included studies. Table 3 re-
orts the study validity criteria that we assessed. Interob-
erver agreement for the various validity criteria that we
ssessed was very good (weighted kappa values ranged from
.71 to 1.00). Considering the issue of ascertainment bias,
he data collectors and outcome adjudicators were
linded in most of the included studies. With the
xception of 1 study, all studies explicitly defined the
riteria used for assessing outcomes (21). No patients
ere lost to follow-up. Most of the included studies were
t risk of overfitted models, because the number of events
er variable included in the multivariable analyses was
an Age of Patients
in Study (yrs) Types of Surgery
Length of
Follow-Up
70 Abdominal, genitourinary, orthopedic,
head and neck
3–17 days
66 Major vascular, abdominal, genitourinary 72 h
74† Abdominal, orthopedic 72 h
68 Thoracic, abdominal, genitourinary,
orthopedic, head and neck, other
30 days
70 Major vascular 30 days‡
57 Thoracic, major vascular, abdominal 30 days
68† Thoracic, major vascular, abdominal 30 days‡
59 Major vascular 30 days
62 Thoracic 8 daysMeanalysis provided by study author.
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October 20, 2009:1599–606 Pre-Operative BNP and Perioperative Risk10, a minimum threshold established in simulation
tudies (Tables 3 and 4) (26).
djusted association between pre-operative BNP or NT-
roBNP and 30-day cardiovascular outcomes. All ad-
usted associations were generated through multivariable logis-
ic regression analyses (Table 4). The 9 eligible studies included
total of 3,281 patients, among whom 314 experienced a
NP and NT-proBNP MeasurementsTable 2 BNP and NT-proBNP Measurements
Author, Year (Ref. #) Marker Assay Manufacture
Dernellis and Panaretou, 2006 (20) BNP AxSYM system Axis Shield Di
Cuthbertson et al., 2007 (18) BNP ADVIA Centaur Bayer
Cuthbertson et al., 2007 (19) BNP ADVIA Centaur Bayer
Yun et al., 2008 (21) NT-proBNP Elecsys 2010 Roche Diagnos
Mahla et al., 2007 (12) NT-proBNP Elecsys ProBNP Roche Diagn
Yeh et al., 2005 (13) NT-proBNP Elecsys 2010 Roche Diagnos
Gibson et al., 2007 (11) BNP Shinoria BNP Shinogi & Co.
Feringa et al., 2006 (16) NT-proBNP Elecsys 2010 Roche Diagnos
Cardinale et al., 2007 (17) NT-proBNP Elecsys 1010 Roche Diagnos
Exact timing of measurement not reported. †Authors employed 6 age- and sex-dependent thres
BNP  brain natriuretic peptide; NT-proBNP  N-terminal pro–B-type natriuretic peptide.
tudy Quality CharacteristicsTable 3 Study Quality Characteristics
Author, Year (Ref. #)
Blinded Data
Collection
(Yes/No)
Blinded
Outcome
Assessment
(Yes/No)
Consisten
Outcome
Assessmen
(Yes/No)
Dernellis and Panaretou,
2006 (20)
Not reported No Yes
Cuthbertson et al., 2007 (18) Yes Yes Yes
Cuthbertson et al., 2007 (19) Yes Yes Yes
Yun et al., 2008 (21) Not reported Not reported No
Mahla et al., 2007 (12) Yes Yes Yes
Yeh et al., 2005 (13) Yes Yes Yes
Gibson et al., 2007 (11) Yes Yes Yes
Feringa et al., 2006 (16) Yes Yes Yes
Cardinale et al., 2007 (17) Yes Yes Yes
Consistent outcome assessment is whether the outcome assessment was the same for all study p
eart disease, history of congestive heart failure or cerebrovascular disease, insulin therapy for di
ASA American Society of Anesthesiologists; CABG coronary artery bypass graft; CAD coron
bstructive pulmonary disease; CRF chronic renal failure; CVA cerebrovascular accident; DM diabet
entricular ejection fraction; LVH  left ventricular hypertrophy; PCI  percutaneous coronary interventioerioperative cardiovascular complication. All the included
tudies demonstrated that a pre-operative BNP or NT-
roBNP measurement was an independent predictor of car-
iovascular outcomes within 30 days of noncardiac surgery.
hree studies in our systematic review adjusted for left ven-
ricular ejection fraction (LVEF) and still reported a statisti-
ally significant association between a pre-operative BNP
BNP Threshold
(pg/ml)
Timing of BNP
Measurement
Proportion of Patients
With Elevated BNP (%)
ics 189 Up to 3 days pre-operative 19.9
40 Within 24 h pre-operative 33.3
170 Immediately pre-operative 37.5
201 Pre-operative* 24.4
280 1 day pre-operative 38.1
450 Immediately pre-operative 23.7
108.5 1 day pre-operative 23.7
533 21  11 days pre-operative 15.3
Various† 24 h pre-operative 17.8
Method of Patient
Follow-Up Variables Adjusted for in Analyses
Chart review DM, CAD (past MI, CABG/PCI, angina as
independent variables), CHF, type of surgery,
hypertension, dyslipidemia, smoking, aortic
stenosis, arrhythmia on last pre-operative ECG,
ST-segment or T-wave changes or left bundle
branch on baseline ECG, LVH on echo, LVEF,
A:E ratio on transmitral Doppler 1, drug use
(including beta-blocker, ACE inhibitor, diuretic),
Goldman index, signs of chronic liver disease,
family history of CAD, sex, age
Direct patient follow-up Revised cardiac risk index;† age and prior use of
cardiac medication in a second model
Direct patient follow-up RCRI, ASA scoring system
Direct patient follow-up History of CAD, history of CHF, intermediate-risk
surgery, RCRI 2, left atrial enlargement,
hemoglobin, LVEF, age, operation time 60
min, diastolic dysfunction, atrial fibrillation,
transfusion, regional wall motion abnormality
Direct patient follow-up CAD, pre-operative creatinine, high-risk surgery
(abdominal aortic aneurysm resection), age,
pre-operative fibrinogen, pre-operative high
sensitivity C-reactive protein, duration of surgery,
surgical complications
Direct patient follow-up ASA grade, pre-operative cardiac impairment, age
Direct patient follow-up CAD, CHF, CVA/TIA, renal impairment, type of
surgery, sex, beta-blocker and statin use
Direct patient follow-up;
chart review
DM, renal failure, DSE WM abnormalities (both
new and at rest)
Direct patient follow-up CAD, high-risk surgery, age, sex, hypertension,
COPD, left atrial size, LVEF, beta-blocker use
nts. †Variables in the Revised Cardiac Risk Index (RCRI) include high-risk type of surgery, ischemic
mellitus, and pre-operative serum creatinine 2.0 mg/dl.
ery disease (including past myocardial infarction); CHF congestive heart failure; COPD chronicr
agnost
tics
ostics
tics
tics
ticst
t*
articipa
abetes
ary artes mellitus; DSE dobutamine stress echocardiography; ECG electrocardiography; LVEF left
n; TIA  transient ischemic attack; WM  wall motion.
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Pre-Operative BNP and Perioperative Risk October 20, 2009:1599–606easurement and a perioperative cardiovascular outcome
17,20,21). These studies suggest that a pre-operative BNP
easurement provides independent prognostic information
eyond LVEF.
We were able to obtain data on events occurring up to
0 days after noncardiac surgery for all 9 studies, either
rom the published reports or by contacting the authors.
eath, cardiac death, and nonfatal MI were part of the
omposite outcome in all but 1 of the studies (17). The
rimary outcome in this study, by Cardinale et al. (17),
as the occurrence of atrial fibrillation. This outcome was
udged to be prognostically distinct from the outcomes in
djusted Association Between Pre-Operative BNP/NT-proBNP LeveTable 4 Adjusted Association Between Pre-Operative BNP/NT-
Author, Year (Ref. #) Outcome Events
Dernellis and Panaretou, 2006 (20) Cardiac death, nonfatal MI, pulmonary
edema, ventricular tachycardia
Cuthbertson et al., 2007 (18) Myocardial injury, death, arrhythmia*
Cuthbertson et al., 2007 (19) Cardiac death, myocardial injury
Yun et al., 2008 (21) Cardiac death, nonfatal MI, pulmonary
edema, nonfatal stroke
Mahla et al., 2007 (12) Nonfatal MI, acute coronary revascularizatio
cardiac death
Yeh et al., 2005 (13) Cardiac death, ACS, heart failure, arrhythmi
Gibson et al., 2007 (11) Cardiac death, nonfatal MI
Feringa et al., 2006 (16) Death, nonfatal MI
Cardinale et al., 2007 (17) Atrial fibrillation
Resulting in hemodynamic compromise or requiring intervention.
ACS  acute coronary syndrome; CI  confidence interval; LR  logistic regression; MI  myoc
Figure 2 Adjusted Odds Ratios for Pre-Operative BNP/NT-proBN
Forest plot showing the individual and pooled adjusted odds ratios from the includ
BNP  brain natriuretic peptide; CI  confidence interval; NT-proBNP  N-terminalhe other studies (i.e., it was thought that this outcome
id not pose an immediate threat of mortality, unlike the
ther study outcomes) and was not included in the pooled
nalysis. In the study by Cuthbertson et al. (19), patients
ould satisfy the definition for myocardial injury if they
ad significant new post-operative electrocardiographic
hanges. Because of concerns about the prognostic dis-
imilarity of this outcome to the outcomes in the other
rials, we did not include the data from this study in the
ooled analysis. The results of the pooled estimate of the
emaining 7 studies were included in our meta-analysis
nd are presented in Figure 2. An elevated pre-operative
Cardiovascular Events at 30 DaysP Level and Cardiovascular Events at 30 Days
Number of
Patients
Number of
Events Adjusted OR 95% CI p Value
1,590 96 34.52 17.08–68.62 0.00001
204 12 7.5 1.9–29.4 0.004
40 11 13.6 1.9–97.8 0.009
279 25 7.6 2.2–26.6 0.003
218 44 5.34 1.04–27.50 0.045
190 15 76.3 8.8–661.8 0.001
190 (41149) 26 (1115) 104.0 20.0–540.0 0.001
170 13 17.2 2.8–106.4 0.002
400 72 27.9 13.2–58.9 0.001
infarction; OR  odds ratio.
Predict Cardiovascular Outcomes at 30 Days After Surgery
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ular outcomes at 30 days (odds ratio [OR]: 19.3, 95%
I: 8.5 to 43.7). There was, however, a moderate amount
f heterogeneity across study results (I2  58%, p 
.03). Our a priori hypotheses (i.e., type of BNP, type of
urgery, blinding of data collectors and outcome adjudi-
ators, number of known predictors adjusted for in
nalysis) did not explain the demonstrated heterogeneity.
The pre-operative BNP measurement was an indepen-
ent predictor of perioperative cardiovascular events among
tudies that only considered the outcomes of death, cardio-
ascular death, or MI (OR: 44.2, 95% CI: 7.6 to 257.0,
2  51.6%) (11,16) and studies that included other out-
omes (OR: 14.7, 95% CI: 5.7 to 38.2, I2  62.2%)
12,13,18,20,21); p value for interaction was 0.28.
iscussion
tatement of principal findings. This meta-analysis sug-
ests that a pre-operative BNP or NT-proBNP measurement
ay facilitate risk stratification of patients undergoing noncar-
iac surgery. An elevated BNP measurement was a powerful
redictor of adverse cardiovascular outcomes at 30 days, inde-
endent of conventional risk factors. There was, however, a
oderate amount of heterogeneity that we could not explain,
nd that weakens the inferences of our findings.
trengths and weaknesses of our systematic review. Our
ystematic review has several strengths. We undertook a
omprehensive search, conducted eligibility decisions and
ata abstraction in duplicate and demonstrated a high
egree of agreement, and obtained or confirmed data with
uthors from 7 of the 9 included studies.
There are several limitations to our systematic review. The
ajority of studies included too many variables in their
ultivariable analyses for the number of events in the study,
nd that may have resulted in unreliable models. Furthermore,
he underlying studies did not evaluate a consistent outcome,
nd there was marked heterogeneity across study results that
e could not explain. Each of the individual odds ratios were,
owever, statistically significant. This finding indicates that the
eterogeneity was entirely quantitative, and although there is
ncertainty regarding the strength of the association, the
vidence strongly suggests that there is an independent asso-
iation between an elevated pre-operative BNP level and an
ncreased risk of an adverse perioperative cardiovascular out-
ome. This relationship is robust both for the outcomes of total
ortality, cardiovascular death, or MI and for the other adverse
ardiovascular outcomes assessed.
Studies reported results as an adjusted OR instead of an
djusted likelihood ratio, which is required to allow physi-
ians to use the BNP results to move from a pre-test
robability to a post-test probability. Further, the wide
onfidence intervals associated with the pooled estimates
e.g., OR: 44.2; 95% CI: 7.6 to 257.0 for the outcomes of
eath, cardiovascular death, or MI) highlight why further
esearch is needed before physicians can reliably use the tesults of a pre-operative BNP measurement to enhance
erioperative risk prediction.
ur systematic review in relation to other systematic
eviews. Our systematic review extends the results reported in
recent systematic review that demonstrated an association
etween elevated pre-operative BNP measurement and peri-
perative cardiovascular outcomes in patients having vascular
urgery (27). However, that review pooled the unadjusted odds
atios. In contrast, we pooled the adjusted odds ratios from the
ligible studies to evaluate whether an elevated pre-operative
NP measurement is an independent predictor of periopera-
ive cardiovascular events. This is an important distinction
ecause the cost associated with measuring a pre-operative
NP level is only justifiable if it provides prognostic informa-
ion in addition to that available from established clinical risk
actors. Therefore, we focused on determining whether a
re-operative BNP measurement is an independent predictor
f a perioperative cardiovascular event. Further, this recent
ystematic review only included studies involving patients who
nderwent vascular surgery.
ow does pre-operative BNP predict risk? The ability of
NP levels to predict outcomes in the perioperative setting
ikely relates to its exquisite sensitivity to changes in ven-
ricular function, both systolic and diastolic. Even the small
hanges in ventricular function induced by transient myocar-
ial ischemia produce measurable changes in plasma BNP
7,28), and proportionately higher levels are found in patients
ith poorer left ventricular function (29). Recent evidence also
uggests that plasma BNP levels reflect the presence and
everity of coronary artery disease among patients with chronic
table coronary disease (30). Thus, it is perhaps not surprising
hat elevated BNP measurements proved a powerful predictor
f cardiovascular outcomes at 30 days, independent of conven-
ional risk factors.
hat is the level of BNP that should be considered
bnormal? The studies we evaluated used different thresh-
lds for BNP and NT-proBNP assays to represent an
bnormal value. Because of the limited number of studies, our
ystematic review cannot provide clear guidance on the level of
NP or NT-proBNP that may be considered abnormal.
oreover, it is unlikely that there is a dichotomous threshold
hat defines a normal or abnormal BNP value. More probably,
erioperative cardiovascular risk increases as BNP concentra-
ions increase.
To establish whether there is a single threshold or a few
mportant BNP thresholds requires the evaluation of a large
umber of patients across the spectrum of perioperative risk
ndergoing a broad range of surgical procedures. We are
urrently conducting a substudy in the 40,000 patient
nternational VISION (Vascular events In noncardiac Sur-
ery patIents cOhort evaluatioN) study. This substudy of
0,000 patients is evaluating whether NT-proBNP is an
ndependent predictor of major vascular complications in
he first 30 days after surgery, and we will also determine if
here is 1 or multiple NT-proBNP thresholds that substan-
ially influence risk prediction.
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his systematic review and meta-analysis suggests that a
re-operative BNP or NT-proBNP concentration is a power-
ul, independent predictor of cardiovascular events in the first
0 days after noncardiac surgery. This test appears to represent
rapid and relatively inexpensive method to enhance pre-
perative cardiovascular risk prediction. Results from the on-
oing VISION NT-proBNP study will help clarify the value
f a pre-operative NT-proBNP measurement in a large ade-
uately powered prospective cohort study.
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